Immunome’s Strong Pipeline Could Drive Shareholder Value

Photo of author
Written By Elizabeth Monroe

Immunome, Inc. (NASDAQ) is a biotechnology company focused on advancing novel therapies for challenging diseases. With a robust pipeline that includes AL102 for desmoid tumors and promising ADC and RLT candidates, Immunome presents a compelling case for investors interested in innovative oncology treatments.

AL102: Phase 3 Ready Asset for Desmoid Tumors

Credits: DepositPhotos

Immunome’s lead asset, AL102, acquired from Ayala Pharmaceuticals, is currently in Phase 3 of the RINGSIDE study for desmoid tumors. This pivotal trial aims to evaluate AL102’s efficacy and safety in treating patients with this rare, noncancerous growth.

Clinical Development and Timeline

Enrollment for Part B of the Phase 3 RINGSIDE study was completed in February 2024, marking a significant milestone. Top-line data from this study is anticipated in the second half of 2025, potentially setting the stage for regulatory submissions and commercialization efforts.

Market Potential: Desmoid Tumors

Desmoid tumors represent a significant unmet medical need, characterized by their unpredictable growth and potential impact on adjacent tissues. The global market for desmoid tumor treatments is projected to grow to $5.49 billion by 2032, underscoring the substantial commercial opportunity for successful therapies like AL102.

Strategic Acquisition and Potential

The acquisition of AL102 underscores Immunome’s strategic approach to bolstering its oncology portfolio. If Phase 3 data demonstrates positive outcomes, Immunome could expedite an NDA filing, positioning AL102 as a potential standard-of-care treatment for desmoid tumors.

Diversification Strategy: Beyond AL102

Immunome mitigates risk and enhances its growth potential through a diversified pipeline. In addition to AL102, the company is advancing two other promising candidates:

IM-1021: Antibody-Drug Conjugate (ADC) Targeting ROR1

IM-1021, an ADC targeting ROR1-expressing solid tumors, is poised to enter Phase 1 clinical trials in Q1 2025. This innovative therapy aims to capitalize on the growing interest in targeted therapies for both hematological malignancies and solid tumors.

IM-3050: Radio-Ligand Therapy (RLT) Targeting FAP

IM-3050, a radio-ligand therapy targeting FAP-expressing solid tumors, represents another cornerstone of Immunome’s pipeline. With an IND submission planned for Q1 2025, IM-3050 aims to address limitations associated with conventional therapies by offering a more targeted and potentially effective treatment option.

Innovative Approach: Immunome Discovery Engine

Immunome leverages its proprietary technology, the “Immunome Discovery Engine,” to identify novel targets and antibodies. This platform has attracted significant interest, leading to a collaboration with AbbVie aimed at developing up to 10 target-antibody pairs. Such collaborations underscore Immunome’s commitment to innovation and expanding therapeutic possibilities in oncology.

Financial Strength and Runway

As of March 31, 2024, Immunome reported cash, cash equivalents, and marketable securities totaling $309.7 million, bolstered by a recent public offering. This strong financial position provides Immunome with ample runway to advance its pipeline through key clinical milestones and regulatory processes, potentially into 2026 without the immediate need for additional funding.

Risks and Challenges

While Immunome’s pipeline holds promise, the biotechnology sector is fraught with inherent risks:

  • Clinical Trial Outcomes: The outcome of Phase 3 trials, particularly AL102’s RINGSIDE study, will heavily influence Immunome’s near-term prospects and market valuation.
  • Regulatory Hurdles: Navigating regulatory pathways, including FDA approval for AL102 and subsequent candidates, poses significant challenges and uncertainties.
  • Market Competition: Established and emerging competitors in the oncology space may impact market adoption and commercial success of Immunome’s therapies.
  • Operational Risks: Execution of clinical trials, managing partnerships like the one with AbbVie, and maintaining financial discipline amid evolving market dynamics are critical for Immunome’s long-term success.

Standing at the Forefront

Credits: DepositPhotos

Immunome stands at the forefront of biotechnological innovation, with AL102 and other promising candidates poised to address critical unmet needs in oncology. With a robust pipeline, strategic partnerships, and strong financial backing, Immunome presents a compelling investment opportunity for those looking to capitalize on advancements in cancer therapeutics.



You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at; the Financial Industry Regulatory Authority (the "FINRA") at, and relevant State Securities Administrator website and the OTC Markets website at The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: and

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.